electroCore Inc (ECOR) posted record net sales of $9.7 million and its lowest operating loss ever, while guiding for 30-40% revenue growth in 2027 and a path to positive adjusted EBITDA by year-end.
Motley Fool Press Release.
ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Toronto 2026 Powered by MicroCapClub being held at the Arcadian Court & Loft. Joshua Lev, Co-CEO, President and CFO, will deliver a presentation and host one-on-one investor meetings throughout the conference. Conference Details: Dates: October 27-29Company Presentation: Wednesday, October
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel. On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference. Investors who wish to reques
Detailed price information for Electrocore Inc (ECOR-Q) from The Globe and Mail including charting and trades.
Internal leadership appointments reflect the Company's confidence in two exceptional leaders whose complementary strengths will enhance shareholder valueROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, ef
Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experienceROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic technology company, today announced that Truvaga, its non-invasive vagus nerve stimulation (nVNS) wellness brand, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The award recognizes T
This is the newest page. Registered accounts read further back.